Starpharma share price charges higher on UK VivaGel BV launch

The Starpharma Holdings Limited (ASX:SPL) share price is pushing higher on Wednesday after announcing the UK launch of its VivaGel BV product…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Starpharma Holdings Limited (ASX: SPL) share price is pushing higher on Wednesday.

In morning trade the dendrimer products developer's shares are up 3% to $1.36.

Why is the Starpharma share price pushing higher?

Investors have been buying Starpharma's shares after it announced that its VivaGel BV product has been launched in the United Kingdom under the brand Betafem BV Gel.

VivaGel BV is a novel, non-antibiotic therapy for the treatment of bacterial vaginosis (BV) and prevention of recurrent BV.

BV is the most common vaginal condition worldwide and twice as common as thrush. One in three women will experience BV and half of these women will have recurrent BV.

Today's news follows the first European launches of the product in June 2019, including in Germany and other countries. It is available over-the-counter in Europe, without the need to see a doctor or obtain a prescription.

Management notes that Europe represents a large commercial opportunity for VivaGel BV, with access to more than 260 million women.

Dr Jackie Fairley, Starpharma CEO, said: "We are delighted to see VivaGel BV launched in the UK. Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV. We look forward to working with Mundipharma on further registrations and launches across the globe."

Mundipharma's CEO, Raman Singh, also spoke positively of the launch.

Singh said: "VivaGel BV is an important addition to the Betadine product portfolio, which continues to evolve to support women's everyday health and well-being around the world. Together with Starpharma we look forward to realising our joint ambition for Betafe and women's health."

The two parties are not resting on their laurels, though. The release explains that they continue to work proactively on regulatory and roll-out activities of VivaGel BV across other Mundipharma's regions.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Starpharma Holdings Limited. The Motley Fool Australia has recommended Starpharma Holdings Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

Two young boys, identical twins, dressed in suave business suits and ties wear sparkly masks over their eyes and pout at the camera.
Share Market News

Investors doubled their money with these ASX 200 shares in a year

These share market winners doubled since this time last year. 

Read more »

Young woman in yellow striped top with laptop raises arm in victory
Broker Notes

Bell Potter says these ASX 200 shares are post-result buys

These results have made the broker even more bullish on them.

Read more »

a close up picture of a man's face with an expression of dumbfounded surprise as he holds his hand to his chin as if thinking further about what has just been revealed to him.
Dividend Investing

ASX 200 average dividend yield drops below 3.5%

The ASX 200 is one of the highest-yielding share markets in the world, with dividends usually averaging 4% to 4.5%…

Read more »

A man in his 30s with a clipped beard sits at his laptop on a desk with one finger to the side of his face and his chin resting on his thumb as he looks concerned while staring at his computer screen.
Share Market News

Down 12% in a month, is this ASX 200 stock a bargain buy?

Bell Potter has given its verdict on this fallen growth share.

Read more »

Three exuberant runners dash towards the camera. One raises her arms in triumph; another jumps in the air with arms raised. The third runner gives a satisfied smile.
Opinions

What to do with your CBA, BHP, and CSL shares now: experts

They're the 3 biggest ASX 200 companies by market capitalisation. Are they a buy, hold, or sell?

Read more »

Young woman dressed in suit sitting at cafe staring at laptop screen with hands to her forehead looking tense
Share Market News

5 things to watch on the ASX 200 on Friday

It looks set to be a tough finish to the week for Aussie investors.

Read more »

A woman sits at her desk thinking. She is surrounded by projections of world maps on various screens with data appearing below them.
Share Market News

Will ASX shares outperform global equities in FY26?

Global equities have delivered superior growth for 3 consecutive years. But is the tide turning?

Read more »

Two smiling work colleagues discuss an investment or business plan at their office.
Broker Notes

Macquarie names 3 top ASX shares to buy now

Let's see which shares the broker has named as buys.

Read more »